Please login to the form below

Not currently logged in
Email:
Password:

GSK to cut 3,000 jobs

GlaxoSmithKline is to announce more than 3,000 job cuts at its European and US operations as a result of a shift in focus to emerging markets

It is reported that GlaxoSmithKline is to announce more than 3,000 job cuts at its European and US operations as a result of a shift in focus from stagnant Western markets to China in particular, and emerging markets in Asia and Latin America.

GSK aims to reduce £1.7bn in annual costs by the end of next year and re-focus efforts on research and development. Demand for the company's Pandremix vaccine against H1N1 has been lower than anticipated and sales of GSK's H1N1 drug Relenza have also fallen short.

Analysts have said that the group is too reliant on aging patents – the company has been hit most recently by generic versions of its herpes treatment Valtrex after expiry of its US patent.

1st February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics